Why Pro Medicus (ASX: PME) is rallying in a falling market
Pro Medicus (ASX: PME) is trading higher this morning following another significant contract win: they announced a 10-year, A$128m agreement with NYC Health + Hospitals, New York City’s public hospital system.
The deal covers PME’s full suite of medical imaging and radiology software, reinforcing its position as a leading global provider of imaging technology.
Importantly, the contract incorporates a transaction-based pricing model, providing potential upside beyond the headline value as imaging volumes grow.
- The announcement is another endorsement of PME’s technology and its ability to secure large, long-term contracts with major US healthcare providers.
Today’s strength is particularly encouraging given PME’s volatile year, with the stock still ~30% below its December 2025 high. The shares suffered a sharp de-rating following February’s half-year result, while the subsequent recovery has partly reflected improving sentiment towards healthcare stocks, but today’s move is firmly around PME.
MM remains long and bullish on PME.